New Market Study, "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013", Has Been Published

Boston, MA -- (SBWIRE) -- 06/26/2013 -- Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Hospital Acquired Pneumonia (HAP) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.